Compare commits
2 commits
c24f0df683
...
3317245d31
| Author | SHA1 | Date | |
|---|---|---|---|
|
3317245d31 | ||
|
|
7e6afa030b |
23 changed files with 30 additions and 337 deletions
|
|
@ -27,12 +27,6 @@ This is not an American problem alone. The American diet and lifestyle are sprea
|
|||
|
||||
The four major risk factors behind the highest burden of noncommunicable disease -- tobacco use, harmful use of alcohol, unhealthy diets, and physical inactivity -- are all lifestyle factors that simple interventions could address. The gap between what science knows works (lifestyle modification) and what the system delivers (pharmaceutical symptom management) represents one of the largest misalignments in the modern economy.
|
||||
|
||||
|
||||
### Additional Evidence (extend)
|
||||
*Source: [[2025-06-01-cell-med-glp1-societal-implications-obesity]] | Added: 2026-03-15*
|
||||
|
||||
GLP-1s may function as a pharmacological counter to engineered food addiction. The population-level obesity decline (39.9% to 37.0%) coinciding with 12.4% adult GLP-1 adoption suggests pharmaceutical intervention can partially offset the metabolic consequences of engineered hyperpalatable foods, though this addresses symptoms rather than root causes of the food environment.
|
||||
|
||||
---
|
||||
|
||||
Relevant Notes:
|
||||
|
|
|
|||
|
|
@ -19,21 +19,15 @@ The competitive dynamics (Lilly vs. Novo vs. generics post-2031) will drive pric
|
|||
|
||||
|
||||
### Additional Evidence (extend)
|
||||
*Source: [[2024-08-01-jmcp-glp1-persistence-adherence-commercial-populations]] | Added: 2026-03-15 | Extractor: anthropic/claude-sonnet-4.5*
|
||||
*Source: 2024-08-01-jmcp-glp1-persistence-adherence-commercial-populations | Added: 2026-03-15 | Extractor: anthropic/claude-sonnet-4.5*
|
||||
|
||||
Real-world persistence data from 125,474 commercially insured patients shows the chronic use model fails not because patients choose indefinite use, but because most cannot sustain it: only 32.3% of non-diabetic obesity patients remain on GLP-1s at one year, dropping to approximately 15% at two years. This creates a paradox for payer economics—the "inflationary chronic use" concern assumes sustained adherence, but the actual problem is insufficient persistence. Under capitation, payers pay for 12 months of therapy ($2,940 at $245/month) for patients who discontinue and regain weight, capturing net cost with no downstream savings from avoided complications. The economics only work if adherence is sustained AND the payer captures downstream benefits—with 85% discontinuing by two years, the downstream cardiovascular and metabolic savings that justify the cost never materialize for most patients.
|
||||
|
||||
|
||||
### Additional Evidence (extend)
|
||||
*Source: [[2025-06-01-cell-med-glp1-societal-implications-obesity]] | Added: 2026-03-15*
|
||||
|
||||
The Cell Press review characterizes GLP-1s as marking a 'system-level redefinition' of cardiometabolic management with 'ripple effects across healthcare costs, insurance models, food systems, long-term population health.' Obesity costs the US $400B+ annually, providing context for the scale of potential cost impact. The WHO issued conditional recommendations within 2 years of widespread adoption (December 2025), unusually fast for a major therapeutic category.
|
||||
|
||||
|
||||
### Additional Evidence (extend)
|
||||
### Additional Evidence (challenge)
|
||||
*Source: [[2025-01-01-select-cost-effectiveness-analysis-obesity-cvd]] | Added: 2026-03-15*
|
||||
|
||||
SELECT trial modeling shows semaglutide is highly cost-effective at net prices ($32K/QALY with 48% rebate) but borderline at list prices ($136K/QALY). Recent Medicare deals at $245/month versus $1,350/month list price fundamentally change the cost-effectiveness calculation. The declining price trajectory may flip GLP-1s from inflationary to cost-effective faster than 2035 projection.
|
||||
At net prices with 48% rebate, semaglutide achieves ICER of $32,219/QALY (highly cost-effective), and Medicare's $245/month deal (~82% discount) would place it well below cost-effectiveness thresholds. The inflationary impact claim may need scope qualification: GLP-1s are inflationary at list prices but potentially cost-saving at actual net prices, and the declining price trajectory may flip the net cost impact faster than 2035.
|
||||
|
||||
---
|
||||
|
||||
|
|
|
|||
|
|
@ -31,10 +31,10 @@ For value-based care models and capitated payers, this multi-organ protection cr
|
|||
- First GLP-1 to receive FDA indication for CKD in T2D patients
|
||||
|
||||
|
||||
### Additional Evidence (confirm)
|
||||
### Additional Evidence (extend)
|
||||
*Source: [[2025-01-01-select-cost-effectiveness-analysis-obesity-cvd]] | Added: 2026-03-15*
|
||||
|
||||
Lifetime modeling quantifies multi-organ savings: $14,431 per subject from avoided T2D, $2,074 from avoided CKD, $1,512 from avoided CV events. Diabetes prevention alone generates 9.6x the economic value of cardiovascular protection, confirming that multi-organ effects compound economic value beyond any single endpoint.
|
||||
Quantified lifetime savings show diabetes prevention ($14,431/subject) as the dominant economic benefit, exceeding CKD savings ($2,074) by 7x and CV event savings ($1,512) by 9.5x. The compounding value is real but asymmetric: metabolic disease prevention drives the economic case more than cardiovascular or renal protection.
|
||||
|
||||
---
|
||||
|
||||
|
|
|
|||
|
|
@ -28,6 +28,12 @@ This is the first dedicated kidney outcomes trial with a GLP-1 receptor agonist,
|
|||
- FDA indication expansion to T2D patients with CKD (2024)
|
||||
- Dialysis cost benchmark: $90K+/year per patient
|
||||
|
||||
|
||||
### Additional Evidence (challenge)
|
||||
*Source: [[2025-01-01-select-cost-effectiveness-analysis-obesity-cvd]] | Added: 2026-03-15*
|
||||
|
||||
SELECT trial modeling shows CKD savings of $2,074/subject versus T2D prevention savings of $14,431/subject. Diabetes prevention, not kidney disease delay, creates the largest per-patient cost savings in this population.
|
||||
|
||||
---
|
||||
|
||||
Relevant Notes:
|
||||
|
|
|
|||
|
|
@ -31,12 +31,6 @@ Since specialization and value form an autocatalytic feedback loop where each am
|
|||
|
||||
The Commonwealth Fund's 2024 international comparison demonstrates this transition empirically across 10 developed nations. All countries compared (Australia, Canada, France, Germany, Netherlands, New Zealand, Sweden, Switzerland, UK, US) have eliminated material scarcity in healthcare — all possess advanced clinical capabilities and universal or near-universal access infrastructure. Yet health outcomes vary dramatically. The US spends >16% of GDP (highest by far) with worst outcomes, while top performers (Australia, Netherlands) spend the lowest percentage of GDP. The differentiator is not clinical capability (US ranks 2nd in care process quality) but access structures and equity — social determinants. This proves that among developed nations with sufficient material resources, social disadvantage (who gets care, discrimination, equity barriers) drives outcomes more powerfully than clinical quality or spending volume.
|
||||
|
||||
|
||||
### Additional Evidence (extend)
|
||||
*Source: [[2025-06-01-cell-med-glp1-societal-implications-obesity]] | Added: 2026-03-15*
|
||||
|
||||
GLP-1 access inequality demonstrates the epidemiological transition in action: the intervention addresses metabolic disease (post-transition health problem) but access stratifies by wealth and insurance status (social disadvantage), potentially widening health inequalities even as population-level outcomes improve. The WHO's emphasis on 'multisectoral action' and 'healthier environments' acknowledges that pharmaceutical solutions alone cannot address socially-determined health outcomes.
|
||||
|
||||
---
|
||||
|
||||
Relevant Notes:
|
||||
|
|
|
|||
|
|
@ -77,12 +77,6 @@ Autocrat v0.1 made the three-day window configurable rather than hardcoded, with
|
|||
|
||||
Proposal #3 on MetaDAO (account EXehk1u3qUJZSxJ4X3nHsiTocRhzwq3eQAa6WKxeJ8Xs) ran on Autocrat version 0.3, created 2024-07-04, and completed/ended 2024-07-08 - confirming the four-day operational window (proposal creation plus three-day settlement period) specified in the mechanism design.
|
||||
|
||||
|
||||
### Additional Evidence (confirm)
|
||||
*Source: [[2025-03-05-futardio-proposal-proposal-1]] | Added: 2026-03-15*
|
||||
|
||||
Production deployment data from futard.io shows Proposal #1 on DAO account De8YzDKudqgeJXqq6i7q82AgxxrQ1JXXfMgouQuPyhY using Autocrat version 0.3, with proposal created, ended, and completed all on 2025-03-05. This confirms operational use of the Autocrat v0.3 implementation in live governance.
|
||||
|
||||
---
|
||||
|
||||
Relevant Notes:
|
||||
|
|
|
|||
|
|
@ -49,7 +49,6 @@ MetaDAO's token launch platform. Implements "unruggable ICOs" — permissionless
|
|||
- **2026-03-05** — [[insert-coin-labs-futardio-fundraise]] launched for Web3 gaming studio (failed, $2,508 / $50K = 5% of target)
|
||||
- **2026-03-05** — [[git3-futardio-fundraise]] failed: Git3 raised $28,266 of $100K target (28.3%) before entering refunding status, demonstrating market filtering even with live MVP
|
||||
- **2024-06-14** — [[futardio-fund-rug-bounty-program]] passed: Approved $5K USDC funding for RugBounty.xyz platform development to incentivize community recovery from rug pulls
|
||||
- **2024-08-28** — MetaDAO proposal to develop futardio as memecoin launchpad with futarchy governance failed. Proposal would have allocated $100k grant over 6 months to development team. Key features: percentage of each new token supply allocated to futarchy DAO, points-to-token conversion within 180 days, revenue distribution to $FUTA holders, immutable deployment on IPFS/Arweave. Proposal rejected by market, suggesting reputational risks outweighed adoption benefits.
|
||||
## Competitive Position
|
||||
- **Unique mechanism**: Only launch platform with futarchy-governed accountability and treasury return guarantees
|
||||
- **vs pump.fun**: pump.fun is memecoin launch (zero accountability, pure speculation). Futardio is ownership coin launch (futarchy governance, treasury enforcement). Different categories despite both being "launch platforms."
|
||||
|
|
|
|||
|
|
@ -1,44 +0,0 @@
|
|||
{
|
||||
"rejected_claims": [
|
||||
{
|
||||
"filename": "futarchy-information-advantage-scales-with-information-asymmetry-converging-to-voting-in-aligned-expert-communities.md",
|
||||
"issues": [
|
||||
"missing_attribution_extractor"
|
||||
]
|
||||
},
|
||||
{
|
||||
"filename": "kpi-conditional-futarchy-is-more-appropriate-than-asset-price-futarchy-for-thinly-traded-organizations-coupled-to-external-market-sentiment.md",
|
||||
"issues": [
|
||||
"missing_attribution_extractor"
|
||||
]
|
||||
},
|
||||
{
|
||||
"filename": "governance-cadence-below-one-proposal-per-month-is-incompatible-with-continuous-futarchy-because-infrequent-decisions-reduce-market-learning-and-liquidity-accumulation.md",
|
||||
"issues": [
|
||||
"missing_attribution_extractor"
|
||||
]
|
||||
}
|
||||
],
|
||||
"validation_stats": {
|
||||
"total": 3,
|
||||
"kept": 0,
|
||||
"fixed": 7,
|
||||
"rejected": 3,
|
||||
"fixes_applied": [
|
||||
"futarchy-information-advantage-scales-with-information-asymmetry-converging-to-voting-in-aligned-expert-communities.md:set_created:2026-03-15",
|
||||
"futarchy-information-advantage-scales-with-information-asymmetry-converging-to-voting-in-aligned-expert-communities.md:stripped_wiki_link:speculative-markets-aggregate-information-through-incentive-",
|
||||
"futarchy-information-advantage-scales-with-information-asymmetry-converging-to-voting-in-aligned-expert-communities.md:stripped_wiki_link:MetaDAOs-futarchy-implementation-shows-limited-trading-volum",
|
||||
"kpi-conditional-futarchy-is-more-appropriate-than-asset-price-futarchy-for-thinly-traded-organizations-coupled-to-external-market-sentiment.md:set_created:2026-03-15",
|
||||
"kpi-conditional-futarchy-is-more-appropriate-than-asset-price-futarchy-for-thinly-traded-organizations-coupled-to-external-market-sentiment.md:stripped_wiki_link:coin-price-is-the-fairest-objective-function-for-asset-futar",
|
||||
"governance-cadence-below-one-proposal-per-month-is-incompatible-with-continuous-futarchy-because-infrequent-decisions-reduce-market-learning-and-liquidity-accumulation.md:set_created:2026-03-15",
|
||||
"governance-cadence-below-one-proposal-per-month-is-incompatible-with-continuous-futarchy-because-infrequent-decisions-reduce-market-learning-and-liquidity-accumulation.md:stripped_wiki_link:MetaDAOs-futarchy-implementation-shows-limited-trading-volum"
|
||||
],
|
||||
"rejections": [
|
||||
"futarchy-information-advantage-scales-with-information-asymmetry-converging-to-voting-in-aligned-expert-communities.md:missing_attribution_extractor",
|
||||
"kpi-conditional-futarchy-is-more-appropriate-than-asset-price-futarchy-for-thinly-traded-organizations-coupled-to-external-market-sentiment.md:missing_attribution_extractor",
|
||||
"governance-cadence-below-one-proposal-per-month-is-incompatible-with-continuous-futarchy-because-infrequent-decisions-reduce-market-learning-and-liquidity-accumulation.md:missing_attribution_extractor"
|
||||
]
|
||||
},
|
||||
"model": "anthropic/claude-sonnet-4.5",
|
||||
"date": "2026-03-15"
|
||||
}
|
||||
|
|
@ -1,7 +1,7 @@
|
|||
{
|
||||
"rejected_claims": [
|
||||
{
|
||||
"filename": "semaglutide-cost-effectiveness-depends-on-net-price-with-48-percent-rebate-producing-32k-per-qaly-versus-136k-at-list-price.md",
|
||||
"filename": "semaglutide-cost-effectiveness-depends-on-net-price-not-list-price-with-48-percent-rebate-creating-32k-per-qaly-versus-136k-at-list.md",
|
||||
"issues": [
|
||||
"missing_attribution_extractor"
|
||||
]
|
||||
|
|
@ -19,11 +19,11 @@
|
|||
"fixed": 2,
|
||||
"rejected": 2,
|
||||
"fixes_applied": [
|
||||
"semaglutide-cost-effectiveness-depends-on-net-price-with-48-percent-rebate-producing-32k-per-qaly-versus-136k-at-list-price.md:set_created:2026-03-15",
|
||||
"semaglutide-cost-effectiveness-depends-on-net-price-not-list-price-with-48-percent-rebate-creating-32k-per-qaly-versus-136k-at-list.md:set_created:2026-03-15",
|
||||
"semaglutide-diabetes-prevention-savings-exceed-cardiovascular-savings-by-10x-with-14431-per-subject-from-avoided-t2d-versus-1512-from-cv-events.md:set_created:2026-03-15"
|
||||
],
|
||||
"rejections": [
|
||||
"semaglutide-cost-effectiveness-depends-on-net-price-with-48-percent-rebate-producing-32k-per-qaly-versus-136k-at-list-price.md:missing_attribution_extractor",
|
||||
"semaglutide-cost-effectiveness-depends-on-net-price-not-list-price-with-48-percent-rebate-creating-32k-per-qaly-versus-136k-at-list.md:missing_attribution_extractor",
|
||||
"semaglutide-diabetes-prevention-savings-exceed-cardiovascular-savings-by-10x-with-14431-per-subject-from-avoided-t2d-versus-1512-from-cv-events.md:missing_attribution_extractor"
|
||||
]
|
||||
},
|
||||
|
|
|
|||
|
|
@ -1,46 +0,0 @@
|
|||
{
|
||||
"rejected_claims": [
|
||||
{
|
||||
"filename": "alignment-impossibility-converges-across-three-mathematical-traditions.md",
|
||||
"issues": [
|
||||
"missing_attribution_extractor"
|
||||
]
|
||||
},
|
||||
{
|
||||
"filename": "reward-hacking-is-globally-inevitable-in-finite-sample-regimes.md",
|
||||
"issues": [
|
||||
"missing_attribution_extractor"
|
||||
]
|
||||
},
|
||||
{
|
||||
"filename": "consensus-driven-objective-reduction-is-the-practical-pathway-out-of-alignment-impossibility.md",
|
||||
"issues": [
|
||||
"missing_attribution_extractor"
|
||||
]
|
||||
}
|
||||
],
|
||||
"validation_stats": {
|
||||
"total": 3,
|
||||
"kept": 0,
|
||||
"fixed": 9,
|
||||
"rejected": 3,
|
||||
"fixes_applied": [
|
||||
"alignment-impossibility-converges-across-three-mathematical-traditions.md:set_created:2026-03-15",
|
||||
"alignment-impossibility-converges-across-three-mathematical-traditions.md:stripped_wiki_link:universal-alignment-is-mathematically-impossible-because-arr",
|
||||
"alignment-impossibility-converges-across-three-mathematical-traditions.md:stripped_wiki_link:single-reward-rlhf-cannot-align-diverse-preferences-because-",
|
||||
"reward-hacking-is-globally-inevitable-in-finite-sample-regimes.md:set_created:2026-03-15",
|
||||
"reward-hacking-is-globally-inevitable-in-finite-sample-regimes.md:stripped_wiki_link:emergent-misalignment-arises-naturally-from-reward-hacking-a",
|
||||
"reward-hacking-is-globally-inevitable-in-finite-sample-regimes.md:stripped_wiki_link:the-specification-trap-means-any-values-encoded-at-training-",
|
||||
"consensus-driven-objective-reduction-is-the-practical-pathway-out-of-alignment-impossibility.md:set_created:2026-03-15",
|
||||
"consensus-driven-objective-reduction-is-the-practical-pathway-out-of-alignment-impossibility.md:stripped_wiki_link:universal-alignment-is-mathematically-impossible-because-arr",
|
||||
"consensus-driven-objective-reduction-is-the-practical-pathway-out-of-alignment-impossibility.md:stripped_wiki_link:community-centred-norm-elicitation-surfaces-alignment-target"
|
||||
],
|
||||
"rejections": [
|
||||
"alignment-impossibility-converges-across-three-mathematical-traditions.md:missing_attribution_extractor",
|
||||
"reward-hacking-is-globally-inevitable-in-finite-sample-regimes.md:missing_attribution_extractor",
|
||||
"consensus-driven-objective-reduction-is-the-practical-pathway-out-of-alignment-impossibility.md:missing_attribution_extractor"
|
||||
]
|
||||
},
|
||||
"model": "anthropic/claude-sonnet-4.5",
|
||||
"date": "2026-03-15"
|
||||
}
|
||||
|
|
@ -1,24 +0,0 @@
|
|||
{
|
||||
"rejected_claims": [
|
||||
{
|
||||
"filename": "marinade-sam-bid-routing-to-mnde-stakers-creates-performance-fee-alignment-between-validator-selection-and-governance-token-holders.md",
|
||||
"issues": [
|
||||
"missing_attribution_extractor"
|
||||
]
|
||||
}
|
||||
],
|
||||
"validation_stats": {
|
||||
"total": 1,
|
||||
"kept": 0,
|
||||
"fixed": 1,
|
||||
"rejected": 1,
|
||||
"fixes_applied": [
|
||||
"marinade-sam-bid-routing-to-mnde-stakers-creates-performance-fee-alignment-between-validator-selection-and-governance-token-holders.md:set_created:2026-03-15"
|
||||
],
|
||||
"rejections": [
|
||||
"marinade-sam-bid-routing-to-mnde-stakers-creates-performance-fee-alignment-between-validator-selection-and-governance-token-holders.md:missing_attribution_extractor"
|
||||
]
|
||||
},
|
||||
"model": "anthropic/claude-sonnet-4.5",
|
||||
"date": "2026-03-15"
|
||||
}
|
||||
|
|
@ -1,35 +0,0 @@
|
|||
{
|
||||
"rejected_claims": [
|
||||
{
|
||||
"filename": "working-group-model-creates-self-sustaining-community-engagement-through-independent-operation-with-initial-core-team-collaboration.md",
|
||||
"issues": [
|
||||
"missing_attribution_extractor"
|
||||
]
|
||||
},
|
||||
{
|
||||
"filename": "futarchy-governed-community-working-groups-use-trial-periods-with-performance-metrics-to-validate-experimental-initiatives.md",
|
||||
"issues": [
|
||||
"missing_attribution_extractor"
|
||||
]
|
||||
}
|
||||
],
|
||||
"validation_stats": {
|
||||
"total": 2,
|
||||
"kept": 0,
|
||||
"fixed": 5,
|
||||
"rejected": 2,
|
||||
"fixes_applied": [
|
||||
"working-group-model-creates-self-sustaining-community-engagement-through-independent-operation-with-initial-core-team-collaboration.md:set_created:2026-03-15",
|
||||
"working-group-model-creates-self-sustaining-community-engagement-through-independent-operation-with-initial-core-team-collaboration.md:stripped_wiki_link:dao-event-perks-as-governance-incentives-create-plutocratic-",
|
||||
"futarchy-governed-community-working-groups-use-trial-periods-with-performance-metrics-to-validate-experimental-initiatives.md:set_created:2026-03-15",
|
||||
"futarchy-governed-community-working-groups-use-trial-periods-with-performance-metrics-to-validate-experimental-initiatives.md:stripped_wiki_link:futarchy-proposals-with-favorable-economics-can-fail-due-to-",
|
||||
"futarchy-governed-community-working-groups-use-trial-periods-with-performance-metrics-to-validate-experimental-initiatives.md:stripped_wiki_link:metadao-autocrat-v01-reduces-proposal-duration-to-three-days"
|
||||
],
|
||||
"rejections": [
|
||||
"working-group-model-creates-self-sustaining-community-engagement-through-independent-operation-with-initial-core-team-collaboration.md:missing_attribution_extractor",
|
||||
"futarchy-governed-community-working-groups-use-trial-periods-with-performance-metrics-to-validate-experimental-initiatives.md:missing_attribution_extractor"
|
||||
]
|
||||
},
|
||||
"model": "anthropic/claude-sonnet-4.5",
|
||||
"date": "2026-03-15"
|
||||
}
|
||||
|
|
@ -1,32 +0,0 @@
|
|||
{
|
||||
"rejected_claims": [
|
||||
{
|
||||
"filename": "glp-1-adoption-produced-first-measurable-population-level-obesity-decline-demonstrating-pharmaceutical-intervention-can-shift-population-health-outcomes.md",
|
||||
"issues": [
|
||||
"missing_attribution_extractor"
|
||||
]
|
||||
},
|
||||
{
|
||||
"filename": "glp-1-access-inequality-risks-creating-two-tier-metabolic-health-system-where-pharmacological-prevention-stratifies-by-wealth-while-root-causes-remain-unaddressed.md",
|
||||
"issues": [
|
||||
"missing_attribution_extractor"
|
||||
]
|
||||
}
|
||||
],
|
||||
"validation_stats": {
|
||||
"total": 2,
|
||||
"kept": 0,
|
||||
"fixed": 2,
|
||||
"rejected": 2,
|
||||
"fixes_applied": [
|
||||
"glp-1-adoption-produced-first-measurable-population-level-obesity-decline-demonstrating-pharmaceutical-intervention-can-shift-population-health-outcomes.md:set_created:2026-03-15",
|
||||
"glp-1-access-inequality-risks-creating-two-tier-metabolic-health-system-where-pharmacological-prevention-stratifies-by-wealth-while-root-causes-remain-unaddressed.md:set_created:2026-03-15"
|
||||
],
|
||||
"rejections": [
|
||||
"glp-1-adoption-produced-first-measurable-population-level-obesity-decline-demonstrating-pharmaceutical-intervention-can-shift-population-health-outcomes.md:missing_attribution_extractor",
|
||||
"glp-1-access-inequality-risks-creating-two-tier-metabolic-health-system-where-pharmacological-prevention-stratifies-by-wealth-while-root-causes-remain-unaddressed.md:missing_attribution_extractor"
|
||||
]
|
||||
},
|
||||
"model": "anthropic/claude-sonnet-4.5",
|
||||
"date": "2026-03-15"
|
||||
}
|
||||
|
|
@ -7,14 +7,10 @@ date: 2025-00-00
|
|||
domain: internet-finance
|
||||
secondary_domains: [collective-intelligence, ai-alignment]
|
||||
format: paper
|
||||
status: null-result
|
||||
status: unprocessed
|
||||
priority: high
|
||||
tags: [futarchy, DeSci, DAOs, empirical-evidence, VitaDAO, simulation, governance-cadence]
|
||||
flagged_for_theseus: ["DeSci governance patterns relevant to AI alignment coordination mechanisms"]
|
||||
processed_by: rio
|
||||
processed_date: 2026-03-15
|
||||
extraction_model: "anthropic/claude-sonnet-4.5"
|
||||
extraction_notes: "LLM returned 3 claims, 3 rejected by validator"
|
||||
---
|
||||
|
||||
## Content
|
||||
|
|
@ -47,10 +43,3 @@ Academic paper examining futarchy adoption in DeSci (Decentralized Science) DAOs
|
|||
PRIMARY CONNECTION: [[speculative markets aggregate information through incentive and selection effects not wisdom of crowds]]
|
||||
WHY ARCHIVED: Peer-reviewed evidence that futarchy converges with voting in low-information-asymmetry environments — defines the boundary condition where markets DON'T beat votes
|
||||
EXTRACTION HINT: Focus on the boundary condition claim — when does futarchy add value vs when does it converge with voting? The information asymmetry dimension is the key variable
|
||||
|
||||
|
||||
## Key Facts
|
||||
- VitaDAO retrospective simulation covered proposals up to April 2025
|
||||
- 13 DeSci DAOs analyzed: AthenaDAO, BiohackerDAO, CerebrumDAO, CryoDAO, GenomesDAO, HairDAO, HippocratDAO, MoonDAO, PsyDAO, VitaDAO, and others
|
||||
- Most DeSci DAOs operate below 1 proposal/month governance frequency
|
||||
- Paper published in Frontiers in Blockchain, peer-reviewed academic journal
|
||||
|
|
|
|||
|
|
@ -12,7 +12,7 @@ priority: medium
|
|||
tags: [glp-1, semaglutide, cost-effectiveness, cardiovascular, SELECT-trial, QALY]
|
||||
processed_by: vida
|
||||
processed_date: 2026-03-15
|
||||
enrichments_applied: ["GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md", "glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md"]
|
||||
enrichments_applied: ["GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md", "glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md", "semaglutide-reduces-kidney-disease-progression-24-percent-and-delays-dialysis-creating-largest-per-patient-cost-savings.md"]
|
||||
extraction_model: "anthropic/claude-sonnet-4.5"
|
||||
---
|
||||
|
||||
|
|
@ -50,9 +50,9 @@ EXTRACTION HINT: Focus on the price sensitivity of the cost-effectiveness conclu
|
|||
|
||||
|
||||
## Key Facts
|
||||
- SELECT trial cost-effectiveness analysis modeled lifetime outcomes for obese/overweight patients with established CVD but without diabetes
|
||||
- Per 100,000 subjects treated (lifetime horizon): 2,791 non-fatal MIs avoided, 3,000 revascularizations avoided, 487 strokes avoided, 115 CV deaths avoided
|
||||
- Average per-subject lifetime treatment cost: $47,353
|
||||
- Australian analysis at A$4,175/year yields ICER of A$96,055/QALY (~US$138K/QALY)
|
||||
- ICER 2025 assessment: semaglutide and tirzepatide now meet <$100K/QALY at net prices (shift from 2022)
|
||||
- Study was industry-funded by Novo Nordisk with 48% rebate as their assumption of actual net pricing
|
||||
- SELECT trial modeling: per 100,000 subjects treated (lifetime horizon): 2,791 non-fatal MIs avoided, 3,000 revascularizations avoided, 487 strokes avoided, 115 CV deaths avoided
|
||||
- Average per-subject lifetime treatment cost for semaglutide 2.4mg: $47,353
|
||||
- Australian semaglutide cost: A$4,175/year with ICER of A$96,055/QALY
|
||||
- Australian cost-effectiveness threshold: A$50,000/QALY
|
||||
- US cost-effectiveness threshold used: $150,000/QALY
|
||||
- Study funded by Novo Nordisk with 48% rebate assumption
|
||||
|
|
|
|||
|
|
@ -6,12 +6,9 @@ url: "https://www.futard.io/proposal/CJW4iZPT14sVNzoc4Yibx1LbnY12sA75gZCP9HZk11U
|
|||
date: 2025-01-13
|
||||
domain: internet-finance
|
||||
format: data
|
||||
status: enrichment
|
||||
status: unprocessed
|
||||
tags: [futardio, metadao, futarchy, solana, governance]
|
||||
event_type: proposal
|
||||
processed_by: rio
|
||||
processed_date: 2026-03-15
|
||||
extraction_model: "anthropic/claude-sonnet-4.5"
|
||||
---
|
||||
|
||||
## Proposal Details
|
||||
|
|
@ -56,13 +53,3 @@ If approved, this proposal would sanction the addition of a JTO Vault to the Tip
|
|||
- Autocrat version: 0.3
|
||||
- Completed: 2025-01-18
|
||||
- Ended: 2025-01-18
|
||||
|
||||
|
||||
## Key Facts
|
||||
- Jito DAO proposal CJW4iZPT14sVNzoc4Yibx1LbnY12sA75gZCP9HZk11UA was proposal number 1 for the DAO
|
||||
- The proposal used Autocrat version 0.3
|
||||
- DAO account: B3PDBD7NCsJyxSdSDFEK38oNKZMBrgkg46TuqqkgAwPp
|
||||
- Proposer account: proPaC9tVZEsmgDtNhx15e7nSpoojtPD3H9h4GqSqB2
|
||||
- Proposal created 2025-01-13, completed and ended 2025-01-18
|
||||
- Discussion occurred on Discord at discord.gg/QtGpxC52Kw
|
||||
- JIP-10 forum discussion: https://forum.jito.network/t/jip-10-decision-market-on-whether-to-adopt-jto-in-the-tiprouter-ncn-protocol-development/463
|
||||
|
|
|
|||
|
|
@ -7,13 +7,9 @@ date: 2025-02-01
|
|||
domain: ai-alignment
|
||||
secondary_domains: [collective-intelligence]
|
||||
format: paper
|
||||
status: null-result
|
||||
status: unprocessed
|
||||
priority: high
|
||||
tags: [impossibility-result, agreement-complexity, reward-hacking, multi-objective, safety-critical-slices]
|
||||
processed_by: theseus
|
||||
processed_date: 2026-03-15
|
||||
extraction_model: "anthropic/claude-sonnet-4.5"
|
||||
extraction_notes: "LLM returned 3 claims, 3 rejected by validator"
|
||||
---
|
||||
|
||||
## Content
|
||||
|
|
@ -52,9 +48,3 @@ Formalizes AI alignment as a multi-objective optimization problem where N agents
|
|||
PRIMARY CONNECTION: [[universal alignment is mathematically impossible because Arrows impossibility theorem applies to aggregating diverse human preferences into a single coherent objective]]
|
||||
WHY ARCHIVED: Third independent impossibility result from multi-objective optimization — convergent evidence from three mathematical traditions strengthens our core impossibility claim
|
||||
EXTRACTION HINT: The convergence of three impossibility traditions AND the "consensus-driven reduction" pathway are both extractable
|
||||
|
||||
|
||||
## Key Facts
|
||||
- Paper presented as oral presentation at AAAI 2026 Special Track on AI Alignment
|
||||
- Formalizes AI alignment as multi-objective optimization problem with N agents and M objectives
|
||||
- Paper identifies 'No-Free-Lunch principle' for alignment: irreducible computational costs regardless of method sophistication
|
||||
|
|
|
|||
|
|
@ -6,12 +6,9 @@ url: "https://www.futard.io/proposal/DnDiyjAcmS3BNmNEJa2ydEbd6DgnddpkyVXJfngdRTz
|
|||
date: 2025-02-04
|
||||
domain: internet-finance
|
||||
format: data
|
||||
status: enrichment
|
||||
status: unprocessed
|
||||
tags: [futardio, metadao, futarchy, solana, governance]
|
||||
event_type: proposal
|
||||
processed_by: rio
|
||||
processed_date: 2026-03-15
|
||||
extraction_model: "anthropic/claude-sonnet-4.5"
|
||||
---
|
||||
|
||||
## Proposal Details
|
||||
|
|
@ -56,12 +53,3 @@ If approved, this proposal would sanction the development and implementation of
|
|||
- Autocrat version: 0.3
|
||||
- Completed: 2025-02-07
|
||||
- Ended: 2025-02-07
|
||||
|
||||
|
||||
## Key Facts
|
||||
- Marinade MIP.5 proposal account: DnDiyjAcmS3BNmNEJa2ydEbd6DgnddpkyVXJfngdRTzF
|
||||
- Marinade DAO account: 9RNQx6cnheD4tzvRCW5Mo1sTo72Vm6PbPj6SFC5aK4fy
|
||||
- Proposal used Autocrat version 0.3
|
||||
- Proposal completed and ended on 2025-02-07
|
||||
- Proposal discussion hosted on Discord: https://discord.gg/Bkc2EMEF6n
|
||||
- Forum discussion at: https://forum.marinade.finance/t/mip-5-sam-bid-routing-to-mnde-stakers/1700
|
||||
|
|
|
|||
|
|
@ -6,12 +6,9 @@ url: "https://www.futard.io/proposal/6TkkCy26HCqxWGt1QgfhFHc6ASikRjk74Gkk4Wfyd7w
|
|||
date: 2025-02-13
|
||||
domain: internet-finance
|
||||
format: data
|
||||
status: enrichment
|
||||
status: unprocessed
|
||||
tags: [futardio, metadao, futarchy, solana, governance]
|
||||
event_type: proposal
|
||||
processed_by: rio
|
||||
processed_date: 2026-03-15
|
||||
extraction_model: "anthropic/claude-sonnet-4.5"
|
||||
---
|
||||
|
||||
## Proposal Details
|
||||
|
|
@ -97,13 +94,3 @@ The DWG will be led by Socrates, bringing 3+ years of crypto marketing expertise
|
|||
- Autocrat version: 0.3
|
||||
- Completed: 2025-02-16
|
||||
- Ended: 2025-02-16
|
||||
|
||||
|
||||
## Key Facts
|
||||
- Drift Working Group proposal account: 6TkkCy26HCqxWGt1QgfhFHc6ASikRjk74Gkk4Wfyd7wR
|
||||
- Drift Working Group proposal number: 2 on futard.io
|
||||
- Drift Working Group budget: 50,000 DRIFT total (15,400 per month for 3 months, 3,800 for initiatives)
|
||||
- Drift Working Group team structure: 1 lead (5,000 DRIFT/month) + 4 members (2,600 DRIFT/month each)
|
||||
- Drift Working Group lead: Socrates, 3+ years crypto marketing experience
|
||||
- Drift Working Group fund management: 2/3 multisig (lead + two Drift team members)
|
||||
- Drift Working Group proposal completed: 2025-02-16
|
||||
|
|
|
|||
|
|
@ -6,7 +6,7 @@ url: "https://www.futard.io/proposal/EksJ2GhxbmhVAdDKP4kThHiuzKwjhq5HSb1kgFj6x2Q
|
|||
date: 2025-03-05
|
||||
domain: internet-finance
|
||||
format: data
|
||||
status: enrichment
|
||||
status: unprocessed
|
||||
tags: [futardio, metadao, futarchy, solana, governance]
|
||||
event_type: proposal
|
||||
processed_by: rio
|
||||
|
|
@ -14,10 +14,6 @@ processed_date: 2025-03-11
|
|||
enrichments_applied: ["MetaDAOs Autocrat program implements futarchy through conditional token markets where proposals create parallel pass and fail universes settled by time-weighted average price over a three-day window.md"]
|
||||
extraction_model: "anthropic/claude-sonnet-4.5"
|
||||
extraction_notes: "This is raw proposal data from futard.io showing a passed proposal. No project name or proposal details provided beyond metadata. The data confirms operational use of Autocrat v0.3 but contains no arguable claims or novel insights—only verifiable transaction facts. Enriches existing claim about MetaDAO's Autocrat implementation with concrete production evidence."
|
||||
processed_by: rio
|
||||
processed_date: 2026-03-15
|
||||
enrichments_applied: ["MetaDAOs Autocrat program implements futarchy through conditional token markets where proposals create parallel pass and fail universes settled by time-weighted average price over a three-day window.md"]
|
||||
extraction_model: "anthropic/claude-sonnet-4.5"
|
||||
---
|
||||
|
||||
## Proposal Details
|
||||
|
|
@ -45,10 +41,3 @@ extraction_model: "anthropic/claude-sonnet-4.5"
|
|||
- Autocrat version: 0.3
|
||||
- Status: Passed
|
||||
- Created, ended, and completed: 2025-03-05
|
||||
|
||||
|
||||
## Key Facts
|
||||
- Proposal #1 on futard.io (account EksJ2GhxbmhVAdDKP4kThHiuzKwjhq5HSb1kgFj6x2Qu) passed on 2025-03-05
|
||||
- DAO account De8YzDKudqgeJXqq6i7q82AgxxrQ1JXXfMgouQuPyhY is using Autocrat version 0.3
|
||||
- Proposer account: 89VB5UmvopuCFmp5Mf8YPX28fGvvqn79afCgouQuPyhY
|
||||
- Proposal lifecycle (created, ended, completed) all occurred on same day: 2025-03-05
|
||||
|
|
|
|||
|
|
@ -6,12 +6,9 @@ url: "https://www.futard.io/proposal/HCHkdhiPh2q9LTyvUpfyfuybPHW7qg1T2vGtiJzGPrs
|
|||
date: 2025-03-05
|
||||
domain: internet-finance
|
||||
format: data
|
||||
status: enrichment
|
||||
status: unprocessed
|
||||
tags: [futardio, metadao, futarchy, solana, governance]
|
||||
event_type: proposal
|
||||
processed_by: rio
|
||||
processed_date: 2026-03-15
|
||||
extraction_model: "anthropic/claude-sonnet-4.5"
|
||||
---
|
||||
|
||||
## Proposal Details
|
||||
|
|
@ -30,11 +27,3 @@ extraction_model: "anthropic/claude-sonnet-4.5"
|
|||
- Autocrat version: 0.3
|
||||
- Completed: 2025-03-08
|
||||
- Ended: 2025-03-08
|
||||
|
||||
|
||||
## Key Facts
|
||||
- Futard.io Proposal #3 (HCHkdhiPh2q9LTyvUpfyfuybPHW7qg1T2vGtiJzGPrsG) was created on 2025-03-05
|
||||
- Proposal #3 used Autocrat version 0.3
|
||||
- Proposal #3 completed and passed on 2025-03-08
|
||||
- Proposal #3 ran on DAO account 5n61x4BeVvvRMcYBMaorhu1MaZDViYw6HghE8gwLCvPR
|
||||
- Proposal #3 was submitted by proposer 89VB5UmvopuCFmp5Mf8YPX28fGvvqn79afCgouQuPyhY
|
||||
|
|
|
|||
|
|
@ -6,12 +6,9 @@ url: "https://www.futard.io/proposal/2dvNKyxKzVuUMcd89wzfuYjX2RKbJps2Srqu4mJ7LEg
|
|||
date: 2025-04-22
|
||||
domain: internet-finance
|
||||
format: data
|
||||
status: enrichment
|
||||
status: unprocessed
|
||||
tags: [futardio, metadao, futarchy, solana, governance]
|
||||
event_type: proposal
|
||||
processed_by: rio
|
||||
processed_date: 2026-03-15
|
||||
extraction_model: "anthropic/claude-sonnet-4.5"
|
||||
---
|
||||
|
||||
## Proposal Details
|
||||
|
|
@ -51,14 +48,3 @@ This would be the test example for transferring the MetaDAO treasury of USDC to
|
|||
- Autocrat version: 0.3
|
||||
- Completed: 2025-04-22
|
||||
- Ended: 2025-04-22
|
||||
|
||||
|
||||
## Key Facts
|
||||
- Test DAO proposal 'Testing v0.3 Transfer' passed on 2025-04-22
|
||||
- Proposal aimed to transfer MetaDAO treasury USDC to v0.4 DAO
|
||||
- Proposal account: 2dvNKyxKzVuUMcd89wzfuYjX2RKbJps2Srqu4mJ7LEgC
|
||||
- Proposal number: 1
|
||||
- DAO account: GCSGFCRfCRQDbqtPLa6bV7DCJz26NkejR182or8PNqRw
|
||||
- Proposer: 8Cwx4yR2sFAC5Pdx2NgGHxCk1gJrtSTxJoyqVonqndhq
|
||||
- Autocrat version: 0.3
|
||||
- Proposal completed and ended: 2025-04-22
|
||||
|
|
|
|||
|
|
@ -7,13 +7,9 @@ date: 2025-06-01
|
|||
domain: health
|
||||
secondary_domains: [entertainment, internet-finance]
|
||||
format: paper
|
||||
status: enrichment
|
||||
status: unprocessed
|
||||
priority: medium
|
||||
tags: [glp-1, obesity, societal-impact, equity, food-systems, population-health, sustainability]
|
||||
processed_by: vida
|
||||
processed_date: 2026-03-15
|
||||
enrichments_applied: ["GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md", "Big Food companies engineer addictive products by hacking evolutionary reward pathways creating a noncommunicable disease epidemic more deadly than the famines specialization eliminated.md", "the epidemiological transition marks the shift from material scarcity to social disadvantage as the primary driver of health outcomes in developed nations.md"]
|
||||
extraction_model: "anthropic/claude-sonnet-4.5"
|
||||
---
|
||||
|
||||
## Content
|
||||
|
|
@ -56,11 +52,3 @@ EXTRACTION HINT: Focus on both the population-level effect AND the equity concer
|
|||
|
||||
flagged_for_clay: ["GLP-1 adoption is reshaping cultural narratives around obesity, body image, and pharmaceutical solutions to behavioral problems — connects to health narrative infrastructure"]
|
||||
flagged_for_rio: ["GLP-1 equity gap creates investment opportunity in access-focused models that serve underserved populations — potential Living Capital thesis"]
|
||||
|
||||
|
||||
## Key Facts
|
||||
- October 2025 Gallup poll: 12.4% of US adults taking GLP-1 for weight loss (30M+ people)
|
||||
- US obesity prevalence: 39.9% (2022) → 37.0% (2025), representing 7.6M fewer obese Americans
|
||||
- WHO issued conditional recommendations for GLP-1s in December 2025
|
||||
- Obesity costs US $400B+ annually
|
||||
- WHO three-pillar approach: healthier environments (population policy), protect high-risk individuals, person-centered care
|
||||
|
|
|
|||
Loading…
Reference in a new issue